Lv63
3040 积分 2021-05-25 加入
Development of a Commercial Manufacturing Process for Vepdegestrant, an Orally Bioavailable PROTAC Estrogen Receptor Degrader for the Treatment of Breast Cancer
4天前
已完结
CDK12 is a promising therapeutic target for the transcription cycle and DNA damage response in metastatic osteosarcoma
1个月前
已完结
RIPTACs: A groundbreaking approach to drug discovery
1个月前
已完结
RIPTACs expand anticancer target space
1个月前
已完结
PROTAC-Mediated Protein Degradation: A Paradigm Shift in Cancer Therapeutics
1个月前
已完结
Inhibitors and PROTACs of CDK2: challenges and opportunities
1个月前
已完结
Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1
2个月前
已完结
The Missing Link(er): A Roadmap to Macrocyclization in Drug Discovery
2个月前
已完结
Advantages and Disadvantages of PROTACs
2个月前
已关闭
Advantages and Disadvantages of PROTACs
2个月前
已关闭
Systematic review of vismodegib toxicity profile in the treatment of advanced basal cell carcinomas compared to other systemic therapies in dermatology
皖公网安备34019202002308
